Payment overview · 2025
General Payments
$113.31
7 reported records · 6 companies
Healthcare provider profile · identity verified
Mitchell Lynn Cardwell, DO
Allopathic & Osteopathic Physicians|Family Medicine · HIBBING, MN · NPI 1790735546
Verified facts
What the public records show
CMS Open Payments records show Mitchell Lynn Cardwell, DO received $113.31 in general payments during 2025 across 7 reported records.
Novartis Pharmaceuticals Corporation accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.55 | 34.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.76 | 13.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.27 | 13.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.71 | 13.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.69 | 13.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.33 | 12.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $113.31 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.55 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 141 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
82 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
141 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 891 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 564 | 89 |
| Losartan Potassium | Losartan Potassium | 541 | 110 |
| Lisinopril | Lisinopril | 498 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 490 | 95 |
| Gabapentin | Gabapentin | 486 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 479 | 108 |
| Omeprazole | Omeprazole | 475 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 459 | 111 |
| Metformin Hcl | Metformin Hcl | 438 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 361 | 72 |
| Simvastatin | Simvastatin | 323 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 293 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 293 | 62 |
| Furosemide | Furosemide | 271 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 267 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 258 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 252 | 43 |
| Trazodone Hcl | Trazodone Hcl | 242 | 33 |
| Sertraline Hcl | Sertraline Hcl | 235 | 28 |
| Celecoxib | Celecoxib | 212 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 210 | 39 |
| Famotidine | Famotidine | 201 | 32 |
| Finasteride | Finasteride | 196 | 46 |
| Tramadol Hcl | Tramadol Hcl | 193 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 188 | 15 |
| Levetiracetam | Levetiracetam | 187 | 17 |
| Warfarin Sodium | Warfarin Sodium | 184 | 36 |
| Potassium Chloride | Potassium Chloride | 175 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 165 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 156 | 22 |
| Montelukast Sodium | Montelukast Sodium | 154 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 148 | 23 |
| Eliquis | Apixaban | 141 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 20 |
| Allopurinol | Allopurinol | 133 | 34 |
| Xarelto | Rivaroxaban | 127 | 22 |
| Pregabalin | Pregabalin | 125 | 22 |
| Prednisone | Prednisone | 122 | 78 |
| Risperidone | Risperidone | 122 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 120 | 54 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 111 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 109 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 46 |
| Atenolol | Atenolol | 100 | 22 |
| Ozempic | Semaglutide | 100 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 15 |
| Lamotrigine | Lamotrigine | 91 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 17 |
| Torsemide | Torsemide | 89 | suppressed |
| Azithromycin | Azithromycin | 83 | 68 |
| Rybelsus | Semaglutide | 82 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 81 | 17 |
| Metformin Hcl Er | Metformin Hcl | 80 | 17 |
| Alendronate Sodium | Alendronate Sodium | 78 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 78 | 17 |
| Carvedilol | Carvedilol | 77 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | suppressed |
| Naproxen | Naproxen | 67 | 27 |
| Ibuprofen | Ibuprofen | 66 | 22 |
| Bupropion Xl | Bupropion Hcl | 65 | 11 |
| Gemfibrozil | Gemfibrozil | 65 | 12 |
| Lorazepam | Lorazepam | 65 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 14 |
| Lansoprazole | Lansoprazole | 64 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | suppressed |
| Mirtazapine | Mirtazapine | 61 | suppressed |
| Baclofen | Baclofen | 59 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 56 | suppressed |
| Memantine Hcl | Memantine Hcl | 55 | suppressed |
| Topiramate | Topiramate | 55 | 11 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Spironolactone | Spironolactone | 54 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 52 | 18 |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 50 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 47 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 11 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 45 | suppressed |
| Sucralfate | Sucralfate | 45 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 15 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Digoxin | Digoxin | 41 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Estradiol | Estradiol | 40 | suppressed |
| Meloxicam | Meloxicam | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 33 | 26 |
| Ramipril | Ramipril | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Testosterone | Testosterone | 32 | suppressed |
| Methotrexate | Methotrexate Sodium | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 24 |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Jantoven | Warfarin Sodium | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 13 |
| Nabumetone | Nabumetone | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 16 |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 25 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Olanzapine Odt | Olanzapine | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Restasis Multidose | Cyclosporine | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $113.31 · 7 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, ELIQUIS, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error